Beyond anti-PD-1 therapy, epidrugs like decitabine demonstrate synergy with anti-CTLA-4 in epithelial ovarian cancer, as evidenced by orthotopic mouse models using the BR5FVB1-Akt cell line. This evidence concerns the gene CTLA4 and ovarian carcinoma.